Abstract
We have identified several patient sera showing potent and broad HIV-1 neutralization. Using antibody adsorption and elution from selected gp120 variants, the neutralizing specificities of the two most broadly reactive sera were mapped to the primary receptor CD4–binding region of HIV-1 gp120. Novel antibodies to the CD4-binding site are elicited in some HIV-1–infected individuals, and new approaches to present this conserved region of gp120 to the immune system may result in improved vaccine immunogens.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Haynes, B.F. & Montefiori, D.C. Expert Rev. Vaccines 5, 579–595 (2006).
Burton, D.R. et al. Nat. Immunol. 5, 233–236 (2004).
Mascola, J.R. et al. J. Infect. Dis. 173, 340–348 (1996).
Wyatt, R. & Sodroski, J. Science 280, 1884–1888 (1998).
Steimer, K.S., Scandella, C.J., Skiles, P.V. & Haigwood, N.L. Science 254, 105–108 (1991).
Stamatos, N.M. et al. J. Virol. 72, 9656–9667 (1998).
Dhillon, A.K. et al. J. Virol. 81, 6548–6552 (2007).
Migueles, S.A. et al. Nat. Immunol. 3, 1061–1068 (2002).
Thali, M. et al. J. Virol. 65, 5007–5012 (1991).
Olshevsky, U. et al. J. Virol. 64, 5701–5707 (1990).
Pantophlet, R. et al. J. Virol. 77, 642–658 (2003).
Wyatt, R. et al. Nature 393, 705–711 (1998).
Kwong, P.D. et al. Structure 8, 1329–1339 (2000).
Parren, P.W. et al. J. Virol. 75, 8340–8347 (2001).
Zhou, T. et al. Nature 445, 732–737 (2007).
Acknowledgements
This research was supported in part by the Intramural Research Program of the Vaccine Research Center and Division of Intramural Research, National Institute of Allergy and Infectious Diseases, US National Institutes of Health. G.M.S. and R.T.W. were supported in part by a grant from the Bill & Melinda Gates Foundation Grand Challenges initiative. R.T.W. also receives funding from the International AIDS Vaccine Initiative. We thank P. Kwong and G. Nabel for helpful suggestions; L. Kong for the core molecular surface figure; L. Chen (Vaccine Research Center) for providing the Fab fragment of F105, which was obtained from the laboratory of M. Posner (Dana Farber Cancer Institute); D. Burton (Scripps Research Institute) for mAb IgG1b12; H. Katinger (Polymun Scientific Inc.) for mAb 2G12; S. Zolla-Pazner (New York University School of Medicine) for mAb 447-52D; J. Sodroski and D. Gabuzda (Dana Farber Cancer Institute), J. Overbaugh (Fred Hutchinson Cancer Research Center), L. Morris (National Institute of Communicable Diseases), D. Montefiori (Duke University), J. Binley (Torrey Pines Institute for Molecular Sciences), L. Stamatatos (Seattle Biomedical Research Institute) and V. Polonis and F. McCutchan (U.S. Military Research Program) for providing virus isolates or functional Env plasmids; other members of the Wyatt laboratory who contributed ideas or reagents to the study; and B. Hartman and M. Cichanowski for help in preparation of the figures.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figs. 1 & 2, Supplementary Tables 1 & 2, Supplementary Methods (PDF 1114 kb)
Rights and permissions
About this article
Cite this article
Li, Y., Migueles, S., Welcher, B. et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 13, 1032–1034 (2007). https://doi.org/10.1038/nm1624
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1624